SEARCH

SEARCH BY CITATION

References

  • Abraham, R.S., Geyer, S.M., Price-Troska, T.L., Allmer, C., Kyle, R.A., Gertz, M.A., Fonseca, R. (2002) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated (AL) amyloidosis. Blood, 101, 38013807.
  • Alexanian, R., Barlogie, B. & Tucker, S. (1990) VAD-based regimens as primary treatment for multiple myeloma. American Journal of Hematology, 33, 8689.
  • Bradwell, A., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. & Drew, R. (2001) Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673680.
  • British Committee for Standards in Haematology. Clinical Haematology Task Force (1995) Guidelines on the provision of facilities for the care of adult patients with haematological malignancies (including leukaemia, lymphoma and severe bone marrow failure). Clinical and Laboratory Haematology, 17, 310.
  • Camoriano, J.K., Greipp, P.R., Bayer, G.K. & Bowie, E.J. (1987) Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. New England Journal of Medicine, 316, 11331135.
  • Cavenagh, J.D. & Oakervee, H. (2003) Thalidomide in multiple myeloma: current status and future prospects. British Journal of Haematology, 120, 1826.
  • Comenzo, R.L. & Gertz, M.A. (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 99, 42764282.
  • Comenzo, R.L., Vosburgh, E., Falk, R.H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L.M., Berk, J.L., Akpek, G., LaValley, M., O'Hara, C., Arkin, C.F., Wright, D.G. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, 36623670.
  • Dhodapkar, M.V., Jagannath, S., Vesole, D., Munshi, N., Naucke, S., Tricot, G. & Barlogie, B. (1997) Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leukemia and Lymphoma, 27, 351356.
  • Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Thernau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A. & Gertz, M.A. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favourable prognostic factor for survival. Journal of Clinical Oncology, 19, 33503356.
  • Dubrey, S., Pollak, A., Skinner, M. & Falk, R.H. (1995) Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. British Heart Journal, 74, 541544.
  • Dubrey, S., Burke, M.M., Khagani, A., Hawkins, P.N., Yacoub, M.H. & Banner, N.R. (2001) Long term results of heart transplantation in patients with amyloid heart disease. Heart, 85, 202207.
  • Duston, M.A., Skinner, M., Shraham, T. & Cohen, A.S. (1987) Diagnosis of amyloidosis by abdominal fat aspiration: analysis of 4 years experience. American Journal of Medicine, 82, 412414.
  • Falk, R.H., Comenzo, R.L. & Skinner, M. (1997) The systemic amyloidoses: current approaches to diagnosis and treatment. New England Journal of Medicine, 337, 898912.
  • Gertz, M.A. (1999) Amyloidosis: recognition, prognosis and conventional therapy. Hematology, 1999, pp. 333–347. American Society of Hematology Education Program Book.
  • Gertz, M.A. & Kyle, R.A. (1986) Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clinic Proceedings, 61, 218223.
  • Gertz, M.A. & Kyle, R.A. (1990) Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Archives of Internal Medicine, 50, 629633.
  • Gertz, M.A. & Kyle, R.A. (1993) Phase II trial of recombinant interferon alpha-2 in the treatment of primary systemic amyloidosis. American Journal of Hematology, 44, 125128.
  • Gertz, M.A., Falk, R.H., Skinner, M., Cohen, A.S. & Kyle, R.A. (1985) Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. American Journal of Cardiology, 55, 1645.
  • Gertz, M.A., Kyle, R.A. & O'Fallon, W.M. (1992) Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Archives of Internal Medicine, 152, 22452250.
  • Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999a) Prospective randomised trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of primary systemic amyloidosis. Journal of Clinical Oncology, 17, 262267.
  • Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999b) Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. American Journal of Hematology, 61, 115119.
  • Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999c) Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Medical Oncology, 16, 104109.
  • Gertz, M.A., Lacy, M.Q., Gastineau, D.A., Inwards, D.J., Chen, M.G., Tefferi, A., Kyle, R.A. & Litzow, M.R. (2000) Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplantation, 26, 963969.
  • Gillmore, J.D., Hawkins, P.N. & Pepys, M.B. (1997) Amyloidosis: a review of recent diagnostic and therapeutic developments. British Journal of Haematology, 99, 245256.
  • Gillmore, J.D., Davies, J., Iqbal, A., Madhoo, S., Russell, N.H. & Hawkins, P.N. (1998) Allogeneic bone marrow transplantation for systemic AL amyloidosis. British Journal of Haematology, 100, 226228.
  • Gillmore, J.D., Apperley, J.F., Craddock, C., Madhoo, S., Pepys, M.B. & Hawkins, P.N. (1999) High-dose melphalan and stem cell rescue for AL amyloidosis. In: Amyloid and Amyloidosis 1998 (ed. by R.A.Kyle & M.A.Gertz), pp. 102104. Parthenon Publishing, Pearl River, NY.
  • Greipp, P.R., Kyle, R.A. & Bowie, E.J. (1979) Factor X deficiency in primary amyloidosis: resolution after splenectomy. New England Journal of Medicine, 301, 10501051.
  • Harrison, C.J., Mazzullo, H., Ross, F.M., Cheung, K.L., Gerrard, G., Harewood, L., Mehta, A., Lachmann, H.J., Hawkins, P.N. & Orchard, K.H. (2002) Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 117, 427435.
  • Hartmann, A., Holdaas, H., Fauchald, P., Nordal, K.P., Berg, K.J. & Talseth, T. (1992) Fifteen years experience with renal transplantation in systemic amyloidosis. Transplant International, 5, 1518.
  • Hawkins, P.N. (1994) Studies with radiolabelled serum amyloid  P component provide evidence for turnover and regression of amyloid deposits in vivo. Clinical Science, 87, 289295.
  • Hawkins, P.N. (2002) Serum amyloid  P component scintigraphy for diagnosis and monitoring amyloidosis. Current Opinions in Nephrology and Hypertension, 11, 649655.
  • Hawkins, P.N., Lavender, J.P. & Pepys, M.B. (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labelled serum amyloid P component. New England Journal of Medicine, 323, 508513.
  • Hosenpud, J.D., DeMarco, T., Frazier, O.H., Uretsky, B.F., Menkis, A.H., O'Connell, J.B., Olivari, M.T. & Valantine, H. (1991) Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation, 84(Suppl. III), 338343.
  • Kumar, S., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Geyer, S., Iturria, N., Allmer, C., Witzig, T.E., Lust, J.A., Greipp, P.R., Kyle, R.A., Litzow, M.R. & Gertz, M.A. (2002) Single agent dexamethasone for induction in patients with multiple myeloma undergoing autologous stem cell transplantation. Blood, 100, 432a (abstract no. 1673).
  • Kyle, R.A. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 4559.
  • Kyle, R.A. & Greipp, P.R. (1978) Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood, 52, 818827.
  • Kyle, R.A., Greipp, P.R. & O'Fallon, M. (1986) Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood, 68, 220224.
  • Kyle, R.A., Linos, A., Beard, C.M., Linke, R.P., Gertz, M.A., O'Fallon, W.M. & Kurland, L.T. (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 79, 18171822.
  • Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Thernau, T.M. (1997) A trial of three regimens for primary amyloidosis: colchicine, melphalan and prednisone and melphalan, prednisone and colchicine. New England Journal of Medicine, 336, 12021207.
  • Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Thernau, T.M. (1999) Long-term survival (10 years or more) in 30 patients with AL amyloidosis. Blood, 93, 10621066.
  • Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D. & Hawkins, P.N. (2002a) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New England Journal of Medicine, 346, 17861791.
  • Lachmann, H.J., Gillmore, J.D., Pepys, M.B. & Hawkins, P.N. (2002b) Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy. Blood, 100, 210a (abstract no. 788).
  • Lachmann, H.J., Gallimore, J.R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. & Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating immunoglobulin free light chains following chemotherapy. British Journal of Haematology, 122, 7884.
  • Libbey, C.A., Skinner, M. & Cohen, A.S. (1983) Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Archives of Internal Medicine, 143, 15491552.
  • Lovat, L.B., Persey, M.R., Madhoo, S., Pepys, M.B. & Hawkins, P.N. (1998) The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut, 42, 727734.
  • Martinez-Vea, A., Garcia, C., Carreras, M., Revert, L. & Oliver, J.A. (1990) End-stage renal disease in systemic amyloidosis: clinical course and outcome on dialysis. American Journal of Nephrology, 10, 283289.
  • Moreau, P., Leblond, V., Bourquelot, P., Facon, T., Huynh, A., Caillot, D., Hermine, O., Attal, M., Hamidou, M., Nedellec, G., Ferrant, A., Audhuy, B., Bataille, R., Milpied, N. & Harousseau, J.-L. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101, 766769.
  • Mumford, A.D., O'Donnell, J., Gillmore, J.D., Manning, R.A., Hawkins, P.N. & Laffan, M. (2000) Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. British Journal of Haematology, 110, 454460.
  • Palladini, G., Anesi, E., Perfetti, V., Obici, L., Invernizzi, R., Balduini, C., Ascari, E. & Merlini, G. (2001) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 113, 10441046.
  • Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C., Hoffmann, T., Jakob-Roetne, R., Norcross, R.D., Kemp, J.A., Yamamura, K., Suzuki, M., Taylor, G.W., Murray, S., Thompson, D., Purvis, A., Kolstoe, S., Wood, S.P. & Hawkins, P.N. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417, 254259.
  • Rajkumar, S.V., Gertz, M.A. & Kyle, R.A. (1998) Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. American Journal of Medicine, 104, 232237.
  • Rubinow, A., Skinner, M. & Cohen, A.S. (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation, 63, 12851288.
  • Saba, N., Sutton, D.M., Ross, H.J., Siu, S., Crump, R.M., Keating, A. & Stewart, A.K. (1999) High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplantation, 24, 853855.
  • Samson, D., Gaminara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M. & Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, 2, 882885.
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Dember, L.M., Finn, K., Falk, R.H., Berk, J.L., Quillen, K. & Skinner, M. (2001) An overview of the use of high dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation, 28, 637642.
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Berk, J.L., Dember, L.M., Finn, K.T. & Skinner, M. (2002) Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 117, 886889.
  • Schey, S.A., Kazmi, M., Ireland, R. & Lakhani, A. (1998) The use of intravenous intermediate dose melphalan and dexamethasone as induction treatment in the management of de novo multiple myeloma. European Journal of Haematology, 61, 306310.
  • Seldin, D.C., Choufani, E., Skinnner, M., Wright, D.G., Dember, L., Weisman, J., Fennessey, S., Finn, K. & Sanchorawala, V. (2001) A phase I/II trial of thalidomide for patients with AL amyloidosis. Blood, 98, 164a (abstract no. 691).
  • Sezer, O., Schmid, P., Schweigert, M., Heider, U., Eucker, J., Harder, H., Sinha, P., Radtke, H. & Possinger, K. (1999) Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplantation, 23, 967969.
  • Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L.A. & Cohen, A.S. (1996) Treatment of 100 patients with primary amyloidosis: a randomised trial of melphalan, prednisone and colchicine versus colchicine alone. American Journal of Medicine, 100, 290298.
  • Wardley, A.M., Jayson, G.C., Goldsmith, D.J., Venning, M.C., Ackrill, P. & Scarffe, J.H. (1998) The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. British Journal of Cancer, 78, 774776.